Abstract: Atrial fi brillation is an important complication of noncardiothoracic surgery and is associated with higher hospital costs and increased morbidity. Strategies of rate versus rhythm control have been compared in several studies and patient populations and generally result in equivalent patient outcomes. Hemodynamically unstable patients should be electrically cardioverted for immediate restoration of sinus rhythm. However, in stable patients, a variety of pharmacologic agents can be selected for either rate or rhythm control. Selection of a particular agent should be based on a patient's comorbidities and preferences, as well as specifi c characteristics of each agent.
T he incidence of postoperative atrial fi brillation is well described in patients undergoing cardiac surgery. 1 Although fewer data are available in other surgical populations, it is well known that patients who develop postoperative supraventricular arrhythmias experience longer hospital stays, increased morbidity, and higher total health care costs. 2 This is particularly important in orthopedic populations, as procedures are performed with increased frequency in patients of advanced age who are prone to atrial fi brillation. Given the signifi cant clinical and fi nancial consequences, review of atrial fi brillation treatment is vitally important for those who care for postoperative patients.
RATE VS RHYTHM CONTROL
When managing a patient who has developed atrial fibrillation postoperatively, an initial strategy of rate control or rhythm control should be selected. Several studies have evaluated the outcomes of rate vs rhythm control in patients with atrial fi brillation, although none have included postoperative patients and some have specifi cally excluded patients with recent cardiac surgery.
Most studies have assessed mortality as the primary endpoint or part of a composite primary endpoint. In the largest of these studies, patients older than 65 years or with risk factors for stroke were randomized to evaluate the effect of these strategies on all-cause mortality. 3 With an average follow-up of 3.5 years, no signifi cant difference was found for mortality. Furthermore, no signifi cant difference was found for the composite secondary endpoint of mortality, disabling stroke or anoxic encephalopathy, major bleeding, or cardiac arrest. Results were validated in a similar trial, 4 although both were criticized for the low rates of patients with concomitant heart failure.
Questions remained on the best approach to treating atrial fi brillation in patients with systolic heart failure until a trial in 2008 specifi cally evaluated rhythm-and rate-control strategies in patients with systolic heart failure. 5 This study included patients with persistent or paroxysmal atrial fi brillation Ͻ1 year in duration who had an ejection fraction Ͻ35% and a history of congestive heart failure. Like the previous studies, no signifi cant difference was found in cardiovascular mortality between treatment arms. It should be noted that since this was a heart failure population, maximally tolerated beta-blocker therapy was recommended in all patients. While signifi cantly more patients in the rate-control group were on beta blockers (88%), a much higher rate of beta blocker use occurred in the rhythm-control group (80%) than in previous trials. 
■ pharmacology update
Several trials also evaluated hospitalization rates between rhythm-and rate-control strategies. In each of these, the rhythm-control group had signifi cantly higher rates of hospitalization vs the rate-control group. 3, [5] [6] [7] This difference was primarily due to hospitalizations for initiation of anti-arrhythmic therapy or repeat cardioversions, but also included hospitalizations for medication-associated side effects.
Given similar rates of morbidity and mortality comparing rate-and rhythm-control strategies, the approach is based on the individual patient and clinical scenario. Unlike randomized trials, patients in clinical practice are often not eligible for both treatment arms and have comorbidities or conditions that limit drug selection. Therefore, the largely equivocal outcomes of rhythm and rate control do not always apply. A rate-control strategy is often appropriate for the management of postoperative atrial fi brillation, especially in patients who are asymptomatic, since postoperative atrial fi brillation is commonly self-limiting. In patients who have signs of hemodynamic instability (hypotension, angina, worsening heart failure), urgent direct-current cardioversion may be necessary. In these patients and others who are refractory to rate control, a rhythm control strategy may be more appropriate. 8 Further discussion of each strategy and individual drug selection follows.
RATE CONTROL STRATEGIES
The goal of rate control is to control the rate of ventricular response to atrial fi brillation. This is primarily achieved through pharmacologic agents that increase the refractory period of atrioventricular-nodal cells. Rate control methods include the use of beta blockers, nondihydropyridine calcium channel blockers, digoxin, or a combination of these agents (Table 1) .
Beta blockers can be used for both acute atrial fi brillation control and long-term maintenance. These agents are fi rst-line for acute atrial fi brillation management in hemodynamically stable patients, especially those with preserved ejection fraction and in states of high adrenergic tone, including postoperative stress. 8 In 1 trial, beta blockers alone were more effective at achieving goal heart rate in patients than digoxin or calcium channel blockers alone. 9 Patients initiated on beta blockers also switched drug classes less frequently than patients taking calcium channel blockers or digoxin. This trend was ■ pharmacology update also observed in patients with systolic heart failure.
Several beta-blocking agents can be administered intravenously for acute heart rate control. Metoprolol and atenolol have both been shown to signifi cantly decrease heart rate at rest and with exertion vs placebo. 10, 11 Esmolol is another attractive option in acute management of atrial fi brillation and is as effective as verapamil for acute heart rate control.
12 Its quick onset and short duration of action make it easily titratable as a drip, although it is associated with a greater incidence of hypotension than atenolol or metoprolol. All 3 of these agents are selective for ␤1-adrenergic receptors, but may lose their selectivity with high doses.
Long-term use of certain beta blockers is associated with decreased mortality in systolic heart failure; however, because beta blockers have negative inotropic activity in addition to negative chronotropic activity, caution should be used in these patients during acute administration. Titration in patients with a low ejection fraction should be executed slowly and with close hemodynamic monitoring. Metoprolol, atenolol, and esmolol are ␤1-selective; thus, they are generally safe to use in asthmatic patients, although caution should be used at higher doses due to loss of ␤1-receptor selectivity.
Digoxin exerts its main effects on heart rate through vagal stimulation, decreasing sympathetic tone and atrioventricular-nodal conduction. Consequently, digoxin is effective at controlling heart rate at rest, but is less effective in states of increased sympathetic activity. This agent may be particularly useful in patients with concomitant systolic heart failure due to its ability to enhance muscle contractility through inotropic effects on the cardiac muscle. However, it is generally not recommended fi rst-line for acute rate control due to its longer onset of action. Digoxin has been shown to enhance rate control in combination with beta blockers or calcium channel blockers vs either agent alone, so it may be useful as an adjunctive therapy. 9 It should also be noted that digoxin has a narrow therapeutic window; therefore, monitoring of drug concentrations, often in coordination with a pharmacist, is recommended.
The nondihydropyridine calcium channel blockers, diltiazem and verapamil, can be used for acute and long-term heart rate control and are effective for heart rate control both at rest and with exertion. 13, 14 Diltiazem and verapamil are both negative inotropes and are generally not recommended in patients with severe systolic heart failure. Due to their vasodilatory properties, they can cause hypotension, especially after acute intravenous administration, although this is more often reported with verapamil than diltiazem. Both agents interact with a signifi cant number of drugs, including digoxin; serum levels of digoxin should be monitored when used concomitantly to prevent toxicity.
RHYTHM CONTROL STRATEGIES
A summary of the agents commonly used for rhythm control is found in Table 2 . Of note, thromboembolic events are well described in patients undergoing cardioversion when atrial fi brillation is present Ͼ48 hours; therefore, anticoagulation according to the American College of Cardiology/American Heart Association guidelines should be considered prior to chemical or electrical cardioversion. 8 Flecainide and propafenone are both effective for cardioversion of recent-onset atrial fi brillation. A signifi cantly faster response is seen with intravenous vs oral administration of either agent. Both agents are contraindicated in systolic heart failure due to negative inotropic effects and risk of cardiac decompensation. Evidence also indicates that fl ecainide increases mortality due to arrhythmias, cardiac arrest, or other cardiac deaths in patients with a history of myocardial infarction. 15 Therefore, fl ecainide is contraindicated in patients with coronary artery disease, and this contraindication has been extended to all other class IC antiarrhythmics, including propafenone.
Amiodarone, a class III antiarrhythmic medication, is effective for acute rhythm conversion, but has a slower onset of action than fl ecainide and propafenone. 16, 17 This delay is likely due to the extensive distribution of amiodarone into the tissues and its long pharmacologic half-life. Thus, a loading dose strategy must be used when initiating amiodarone (Table 2) .
Amiodarone is also an effective rate control agent, since it possesses both beta-adrenergic and calcium channel-blocking activity. 16 Consequently, patients who experience episodes of atrial fi brillation while on amiodarone may continue to be effectively rate controlled. Another potential advantage includes its established safety in patients with a history of systolic heart failure or coronary artery disease. Potential long-term side effects require monitoring and often preclude amiodarone from being the drug of choice in younger patients requiring long-term therapy (Table 2) .
Other class III antiarrhythmics include the recently Food and Drug Administration-approved dronedarone, sotalol, dofetilide, and ibutilide. Dronedarone is pharmacodynamically similar to amiodarone, and while it has not been studied for cardio- 18 It is important to consider that unlike other medications in this class, it is contraindicated in patients with severe heart failure due to increased mortality. 19 Recent concerns have also been raised over hepatotoxicity risk.
Sotalol and dofetilide have important niches in therapy; however, both carry a relatively high risk of torsades de pointes and should be initiated in the hospital under the direction of a trained electrophysiologist. In other comparator trials, sotalol was less effective for cardioversion than fl ecainide, propafenone, or ibutilide, but was an effective agent for rhythm maintenance after cardioversion. 20 Dofetilide has been shown effective for cardioversion and maintenance of sinus rhythm vs placebo and sotalol. 17, 21 Both agents can be used in patients with coronary artery disease and systolic heart failure. 22 Ibutilide is indicated only for cardioversion vs maintenance of sinus rhythm. In trials, it was more effective than placebo and outperformed both intravenous procainamide and intravenous sotalol for cardioversion within 30 to 90 minutes. 23 Ibutilide may also be useful for cardioversion in patients refractory to propafenone or amiodarone and is most effi cacious for terminating arrhythmias of shorter duration. 24, 25 Like sotalol, ibutilide is associated with high rates of torsades de pointes and must be administered under supervision. 26 Patients should be supervised for at least 4 hours following ibutilide infusion for potential electrocardiogram changes. Magnesium and potassium levels should be within the upper limits of normal, and patients are often supplemented prophylactically to minimize the potential for arrhythmias. Use should be avoided in patients with coronary artery disease or systolic heart failure due to higher risk of arrhythmias. 
■ pharmacology update
Procainamide is not generally recommended for cardioversion of acute atrial fi brillation due to relative lack of effi cacy vs placebo and other antiarrhythmic agents, such as ibutilide and fl ecainide. 27 However, procainamide is the drug of choice in hemodynamically stable patients with Wolf-Parkinson-White syndrome, since it does not block atrioventricular-nodal conduction. 28 Hypotension is a common side effect associated with procainamide and should be considered prior to use.
Pharmacological cardioversion may be advantageous in some patients with acute atrial fi brillation, although individual characteristics of each drug must be considered prior to selection. Both pharmacological and direct-current cardioversion should be performed in coordination with a cardiologist, electrophysiologist, and/ or clinical pharmacy specialist to ensure optimal patient outcomes.
ANTITHROMBOTIC PREVENTION OF STROKE
It is important to consider long-term stroke prevention strategies for patients in atrial fi brillation Ͼ48 hours postoperatively or with a history of atrial fi brillation (paroxysmal, persistent, or chronic), as these individuals are at increased risk of stroke compared to age-matched controls. When initiating drug therapy, the patient's risk of stroke should outweigh the bleeding risks of stroke prevention, especially in the setting of surgery. Risk of stroke is often determined using the CHADS2 index. Patients at low risk of stroke may be initiated on aspirin 81 to 325 mg daily, while more aggressive stroke prevention is recommended in moderate-tohigh-risk patients using agents such as warfarin and dabigatran.
Warfarin, a vitamin K antagonist, has been the staple of long-term anticoagulation for years but requires consistent laboratory monitoring of the patient's international normalized ratio and has many drug and dietary interactions. Dabigatran, an oral direct thrombin inhibitor, has recently been added to the atrial fi brillation guidelines. 29 Dabigatran was shown to be superior to warfarin for occurrence of stroke or systemic embolism and was also associated with less minor bleeds, hemorrhagic strokes, and major life-threatening bleeds. 30 It does not require laboratory monitoring and is not associated with signifi cant drug interactions, but it requires dose adjustment in renal dysfunction and is not reversible in the setting of a major bleed. 
THE BOTTOM LINE
• Orthopedic surgery patients are often at risk for developing postoperative atrial fi brillation due to stress, comorbidities, and increased age.
• In the presence of hemodynamic instability, direct-current cardioversion is indicated for immediate restoration of sinus rhythm.
• Strategies of rate control and rhythm control exhibit similar outcomes in most studies; pharmacologic therapy should be based on specifi c characteristics of each agent, the acuity of the situation, patient comorbidities, and patient preference.
• Aspirin is recommended for stroke prevention in patients with minimal additional risk factors, while long-term anticoagulation is recommended in patients at moderate to high risk of stroke.
• Management of atrial fi brillation should be executed in coordination with a cardiologist, electrophysiologist, and/or clinical pharmacy specialist. 
